ca7ac1e1-4c44-40a5-8094-eeebc0c2c5a2
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 56
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.160
- WNT_BETA_CATENIN_SIGNALING+0.130
- PROTEIN_SECRETION+0.120
- UV_RESPONSE_DN+0.100
- KRAS_SIGNALING_DN+0.080
- MYOGENESIS+0.080
- PANCREAS_BETA_CELLS+0.070
- TGF_BETA_SIGNALING+0.060
- APICAL_JUNCTION+0.050
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.040
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.540
- ALLOGRAFT_REJECTION-0.480
- INFLAMMATORY_RESPONSE-0.450
- TNFA_SIGNALING_VIA_NFKB-0.420
- IL6_JAK_STAT3_SIGNALING-0.390
- CHOLESTEROL_HOMEOSTASIS-0.360
- E2F_TARGETS-0.350
- MTORC1_SIGNALING-0.340
- FATTY_ACID_METABOLISM-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518450 | — | A | 0.883 |
| 2 | SRR8613752 | — | A | 0.880 |
| 3 | ea89121f-2c74-433d-8047-898dc963bf35 | — | — | 0.876 |
| 4 | TCGA-WA-A7H4-01A-21R-A34R-07 | — | — | 0.870 |
| 5 | TCGA-A8-A0A4-01A-11R-A00Z-07 | — | A | 0.862 |
| 6 | d69e622a-6dee-48f3-bf06-7f6148d7472a | — | — | 0.861 |
| 7 | TCGA-OR-A5L8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.860 |
| 8 | SRR8613756 | — | E | 0.860 |
| 9 | 718c4754-af81-496f-878d-83222a2581b8 | — | — | 0.860 |
| 10 | TCGA-CN-A49A-01A-11R-A24H-07 | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.040 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |